Zocor curbs smoking-related lung damage, in rats

Key points
- Treatment with the cholesterol-lowering drug simvastatin, better known as Zocor, can inhibit the lung damage that occurs with smoking-induced Chronic obstructive pulmonary disease (COPD), according to findings from an animal study.
- The leading cause of COPD is smoking, which can lead to the two most common forms of this disease, emphysema and chronic bronchitis.
- In addition to blocking the formation of cholesterol, "statin" drugs have been shown to have anti-inflammatory and anti-oxidant effects, as well as other benefits for blood vessels.
- Sang-Do Lee, from Asan Medical Center in Seoul, Korea, and colleagues examined the lungs of rats exposed or not exposed to cigarette smoke while being treated with or without simvastatin for 16 weeks.
Treatment with the cholesterol-lowering drug simvastatin, better known as Zocor, can inhibit the lung damage that occurs with smoking-induced Chronic obstructive pulmonary disease (COPD), according to findings from an animal study.
In addition to blocking the formation of cholesterol, "statin" drugs have been shown to have anti-inflammatory and anti-oxidant effects, as well as other benefits for blood vessels. In theory, all of these effects could help counter the lung damage caused by cigarette smoking.
To investigate, Dr. Sang-Do Lee, from Asan Medical Center in Seoul, Korea, and colleagues examined the lungs of rats exposed or not exposed to cigarette smoke while being treated with or without simvastatin for 16 weeks.
The researchers' findings are reported in the American Journal of Respiratory and Critical Care Medicine.
Chronic obstructive pulmonary disease (COPD) is a group of lung diseases involving limited airflow and varying degrees of air sac enlargement, airway inflammation, and lung tissue destruction. Emphysema and chronic bronchitis are the most common forms of COPD.
Causes, incidence, and risk factors
The leading cause of COPD is smoking, which can lead to the two most common forms of this disease, emphysema and chronic bronchitis.
Prolonged tobacco use causes lung inflammation and variable degrees of air sac (alveoli) destruction. This leads to inflamed and narrowed airways (chronic bronchitis) or permanently enlarged air sacs of the lung with reduced lung elasticity (emphysema). Between 15% and 20% of long-term smokers will develop COPD.
In addition to blocking lung tissue destruction and high blood pressure in the lungs' circulation, simvastatin inhibited the infiltration of inflammatory cells into pulmonary tissue. As anticipated, the drug also had beneficial effects on blood vessels.
"Taken together, these findings indicate that statins could potentially play a role in the treatment of cigarette smoking-induced COPD," the researchers conclude.
SOURCE: American Journal of Respiratory and Critical Care Medicine, October 15, 2005.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Heart & Blood Vessels →
NewsBeta-Blockers May Be Associated With Benefits in Patients With Lung Disease
Patients with chronic obstructive pulmonary disease (COPD) may have fewer respiratory flare-ups and longer survival if they take beta-blocker medications, according to a report in the May 24 issue of Archives of…
26 May 2010
NewsAnti-inflammatory drugs can help block hypertension-related kidney damage
Anti-inflammatory drugs appear to help block the rapid kidney destruction that can occur with hypertension, Medical College of Georgia researchers report. Treating hypertensive rats with the broad-acting…
12 May 2010
NewsObesity, smoking may raise blood clot risk
Obesity and smoking may each raise a person's risk of potentially dangerous blood clots in the veins, but certain other suspected risk factors seem to have no impact, a new study finds. The study, reported in the…




